{"id":"discontinuation-of-disease-modifying-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Disease flare or relapse"},{"rate":null,"effect":"Loss of disease control"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Discontinuation of disease-modifying therapy refers to a therapeutic strategy or study protocol where patients stop taking medications designed to slow or halt disease progression. This is typically studied to assess disease flare risk, remission durability, or optimal treatment duration rather than representing a pharmacological agent itself.","oneSentence":"This is not a drug but a clinical intervention involving the cessation of disease-modifying antirheumatic therapy (DMARD) or similar disease-modifying treatments.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:35:23.980Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Assessment of disease flare risk following DMARD discontinuation in rheumatoid arthritis or other autoimmune conditions"}]},"trialDetails":[{"nctId":"NCT05306353","phase":"PHASE2","title":"CD40L Antagonism in Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-07-25","conditions":"Rheumatoid Arthritis","enrollment":2},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT05658497","phase":"","title":"Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)","status":"RECRUITING","sponsor":"Biogen","startDate":"2023-10-27","conditions":"Multiple Sclerosis","enrollment":908},{"nctId":"NCT04754542","phase":"","title":"Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2021-05-18","conditions":"Multiple Sclerosis","enrollment":76},{"nctId":"NCT03652961","phase":"PHASE4","title":"Rheumatoid Arthritis Memory B Cells and Abatacept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-02","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT03073603","phase":"PHASE4","title":"Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-04-20","conditions":"Multiple Sclerosis","enrollment":259},{"nctId":"NCT01911767","phase":"","title":"Biogen Multiple Sclerosis Pregnancy Exposure Registry","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-10-30","conditions":"Multiple Sclerosis, Exposure During Pregnancy","enrollment":408},{"nctId":"NCT04260711","phase":"NA","title":"Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-07-01","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive","enrollment":130},{"nctId":"NCT02349295","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-12-31","conditions":"Psoriatic Arthritis","enrollment":363},{"nctId":"NCT02433184","phase":"PHASE4","title":"Very Early Versus Delayed Etanercept in Patients With RA","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":120},{"nctId":"NCT01941095","phase":"PHASE3","title":"A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-20","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT00514982","phase":"PHASE2","title":"Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-08-07","conditions":"Hermanski-Pudlak Syndrome, Colitis, Cytokines","enrollment":""},{"nctId":"NCT01489384","phase":"","title":"Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)","status":"UNKNOWN","sponsor":"Pope Research Corporation","startDate":"2011-12","conditions":"Rheumatoid Arthritis","enrollment":125},{"nctId":"NCT02915354","phase":"PHASE4","title":"Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2007-07","conditions":"Spondylitis, Ankylosing, Recurrence","enrollment":35},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT02775110","phase":"PHASE4","title":"Natalizumab Temporary Discontinuation Study","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2012-11","conditions":"Multiple Sclerosis","enrollment":50},{"nctId":"NCT00810199","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":556},{"nctId":"NCT01137851","phase":"","title":"Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-11","conditions":"Rheumatoid Arthritis","enrollment":3940}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":276,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Discontinuation of disease modifying therapy","genericName":"Discontinuation of disease modifying therapy","companyName":"University of Colorado, Denver","companyId":"university-of-colorado-denver","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is not a drug but a clinical intervention involving the cessation of disease-modifying antirheumatic therapy (DMARD) or similar disease-modifying treatments. Used for Assessment of disease flare risk following DMARD discontinuation in rheumatoid arthritis or other autoimmune conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}